Sustiva data

DuPont Merck presented data at the Infectious Diseases Society of America meeting in San Francisco from an ongoing Phase II study comparing the combination of Sustiva and Merck's Crixivan indinavir HIV protease inhibitor against indinavir alone.

Data were given for 101 asymptomatic or mildly symptomatic patients (CD4 counts of 100-500 and >20,000 copies of HIV RNA/ml) treated for 48 weeks. A total of 59 patients received 200 mg/day Sustiva and 800 or 1000 mg indinavir every 8 hours. A total of 42 patients began the trial on indinavir alone, but could add Sustiva and Bristol-Myers Squibb's Zerit stavudine ( d4T) after 12 weeks. Doses of Sustiva for both arms of the study were raised to 600 mg/day after 36 weeks. ...